Treatment with axitinib rebalances CH-derived hematopoiesis. Recipient mice (CD45.1) competitively transplanted with Dnmt3a^+/Δ and control Dnmt3a^+/+ BM (CD45.2) were treated with axitinib (25 mg/kg per os, three weekly doses) while being administered DSS. Composition of the CH-derived (CD45.2) peripheral blood was analyzed after 70 d of treatment (n = 5–10 from one experiment, Mann–Whitney test). **, P ≤ 0.01; ***, P ≤ 0.001; ns, not significant.